MedPath
HSA Approval

DURATOCIN RTS SOLUTION FOR INJECTION 100 MCG/ML

SIN15173P

DURATOCIN RTS SOLUTION FOR INJECTION 100 MCG/ML

DURATOCIN RTS SOLUTION FOR INJECTION 100 MCG/ML

February 8, 2017

FERRING PHARMACEUTICALS PRIVATE LIMITED

FERRING PHARMACEUTICALS PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFERRING PHARMACEUTICALS PRIVATE LIMITED
Licence HolderFERRING PHARMACEUTICALS PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

**4.2 Posology and method of administration** Posology _Caesarean section under epidural or spinal anaesthesia:_ Withdraw 1 ml of DURATOCIN® RTS containing 100 micrograms carbetocin and administer only by intravenous injection, under adequate medical supervision in a hospital. _Vaginal delivery:_ Withdraw 1 ml of DURATOCIN® RTS containing 100 micrograms carbetocin and administer by intravenous injection or intramuscular injection, under adequate medical supervision in a hospital. Method of administration For intravenous or intramuscular administration. Carbetocin must only be administered after delivery of the infant, and as soon as possible after delivery, preferably before the delivery of the placenta. For intravenous administration carbetocin must be administered slowly, over 1 minute. DURATOCIN® RTS is intended for single use only. No further doses of carbetocin should be administered. _Paediatric population_ There is no relevant use of carbetocin in children below 12 years of age. The safety and efficacy of carbetocin in adolescents has not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.

INTRAVENOUS

Medical Information

**4.1 Therapeutic indications** DURATOCIN® RTS is indicated for the prevention of postpartum haemorrhage due to uterine atony.

**4.3 Contraindications** Pregnancy and labour before delivery of the infant. Induction of labour. Serious cardiovascular disorders. Hypersensitivity to carbetocin or oxytocin or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.

H01BB03

carbetocin

Manufacturer Information

FERRING PHARMACEUTICALS PRIVATE LIMITED

Ferring GmbH

Active Ingredients

Carbetocin

100 mcg/ml

Carbetocin

Documents

Package Inserts

Duratocin RTS Injection PI.pdf

Approved: May 24, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DURATOCIN RTS SOLUTION FOR INJECTION 100 MCG/ML - HSA Approval | MedPath